- Home
- GRAL vs GYRE Comparison
GRAL vs GYRE Comparison
Compare GRAL & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAL
- GYRE
- Stock Information
- Founded
- GRAL 2016
- GYRE 2002
- Country
- GRAL United States
- GYRE United States
- Employees
- GRAL N/A
- GYRE N/A
- Industry
- GRAL
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- GRAL
- GYRE Health Care
- Exchange
- GRAL NYSE
- GYRE Nasdaq
- Market Cap
- GRAL 877.1M
- GYRE 897.1M
- IPO Year
- GRAL N/A
- GYRE N/A
- Fundamental
- Price
- GRAL $37.50
- GYRE $7.68
- Analyst Decision
- GRAL Buy
- GYRE
- Analyst Count
- GRAL 3
- GYRE 0
- Target Price
- GRAL $31.50
- GYRE N/A
- AVG Volume (30 Days)
- GRAL 1.6M
- GYRE 355.4K
- Earning Date
- GRAL 05-13-2025
- GYRE 05-09-2025
- Dividend Yield
- GRAL N/A
- GYRE N/A
- EPS Growth
- GRAL N/A
- GYRE N/A
- EPS
- GRAL N/A
- GYRE 0.02
- Revenue
- GRAL $130,711,000.00
- GYRE $100,643,000.00
- Revenue This Year
- GRAL $19.98
- GYRE $22.01
- Revenue Next Year
- GRAL $17.52
- GYRE $88.14
- P/E Ratio
- GRAL N/A
- GYRE $102.14
- Revenue Growth
- GRAL 30.47
- GYRE N/A
- 52 Week Low
- GRAL $12.33
- GYRE $6.11
- 52 Week High
- GRAL $63.99
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- GRAL N/A
- GYRE 39.36
- Support Level
- GRAL N/A
- GYRE $9.26
- Resistance Level
- GRAL N/A
- GYRE $11.61
- Average True Range (ATR)
- GRAL 0.00
- GYRE 1.11
- MACD
- GRAL 0.00
- GYRE -0.32
- Stochastic Oscillator
- GRAL 0.00
- GYRE 2.38
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.